1
|
Arakil N, Akhund SA, Elaasser B, Mohammad KS. Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis. Biomedicines 2024; 12:1075. [PMID: 38791037 PMCID: PMC11117796 DOI: 10.3390/biomedicines12051075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 04/27/2024] [Accepted: 05/10/2024] [Indexed: 05/26/2024] Open
Abstract
The phenomenon of bone metastases presents a significant challenge within the context of advanced cancer treatments, particularly pertaining to breast, prostate, and lung cancers. These metastatic occurrences stem from the dissemination of cancerous cells into the bone, thereby interrupting the equilibrium between osteoblasts and osteoclasts. Such disruption results in skeletal complications, adversely affecting patient morbidity and quality of life. This review discusses the intricate interplay between cancer cells and the bone microenvironment, positing the bone not merely as a passive recipient of metastatic cells but as an active contributor to cancer progression through its distinctive biochemical and cellular makeup. A thorough examination of bone structure and the dynamics of bone remodeling is undertaken, elucidating how metastatic cancer cells exploit these processes. This review explores the genetic and molecular pathways that underpin the onset and development of bone metastases. Particular emphasis is placed on the roles of cytokines and growth factors in facilitating osteoclastogenesis and influencing osteoblast activity. Additionally, this paper offers a meticulous critique of current diagnostic methodologies, ranging from conventional radiography to advanced molecular imaging techniques, and discusses the implications of a nuanced understanding of bone metastasis biology for therapeutic intervention. This includes the development of targeted therapies and strategies for managing bone pain and other skeletal-related events. Moreover, this review underscores the imperative of ongoing research efforts aimed at identifying novel therapeutic targets and refining management approaches for bone metastases. It advocates for a multidisciplinary strategy that integrates advancements in medical oncology and radiology with insights derived from molecular biology and genetics, to enhance prognostic outcomes and the quality of life for patients afflicted by this debilitating condition. In summary, bone metastases constitute a complex issue that demands a comprehensive and informed approach to treatment. This article contributes to the ongoing discourse by consolidating existing knowledge and identifying avenues for future investigation, with the overarching objective of ameliorating patient care in the domain of oncology.
Collapse
Affiliation(s)
| | | | | | - Khalid S. Mohammad
- Department of Anatomy, College of Medicine, Alfaisal University, Riyadh 1153, Saudi Arabia; (N.A.); (S.A.A.); (B.E.)
| |
Collapse
|
2
|
Rybczyńska M, Sikorski A. Structural insight and in silico prediction of the pharmacokinetic parameters and toxicity of alkaline earth metal compounds strontium and barium with the non-steroidal anti-inflammatory drug nimesulide. Dalton Trans 2024; 53:6501-6506. [PMID: 38511607 DOI: 10.1039/d4dt00446a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
In the crystals of alkaline earth metal compounds strontium and barium with the non-steroidal anti-inflammatory drug nimesulide, the strontium cation is nine-coordinated with a distorted tricapped trigonal prismatic geometry TCTPR-9, whereas the ten-coordinated barium ion exhibits a distorted tetracapped trigonal prismatic geometry TCTPR-10.
Collapse
Affiliation(s)
| | - Artur Sikorski
- Faculty of Chemistry, University of Gdansk, W. Stwosza 63, 80-308 Gdansk, Poland.
| |
Collapse
|
3
|
Sato S, Tomitori H, Okawa A, Akano K. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study. Int J Clin Oncol 2023; 28:1227-1235. [PMID: 37314600 DOI: 10.1007/s10147-023-02365-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 05/31/2023] [Indexed: 06/15/2023]
Abstract
BACKGROUND Real-world data on optimal cancer pain management remain scarce. We describe prescription patterns of analgesics in Japanese cancer patients with bone metastases. METHODS National hospital-based claims data were analyzed. Adults with first diagnosis of cancer during 2015-2019 and first diagnosis of bone metastasis after the initial cancer diagnosis were included. Skeletal-related events (SREs) were identified with disease and receipt codes. RESULTS Among the 40,507 eligible patients (age [mean ± SD], 69.7 ± 11.7 years), lung (25.3%), prostate (15.6%), breast (10.9%), and colorectal (10.7%) cancers were common primary tumors. Time (mean ± SD) between primary cancer diagnosis and bone metastases was 306.9 ± 490.4 days; median survival time from bone metastases was 483.0 days. Most patients used acetaminophen (62.7%, 117.5 days/year) and nonsteroidal anti-inflammatory drugs (NSAIDs; 75.3%, 170.0 days/year). Commonly used opioids included oxycodone (39.4%; 479.3 days/year), fentanyl (32.5%; 52.6 days/year), morphine (22.1%; 130.9 days/year), and tramadol (15.3%; 143.0 days/year). Internal medicine, surgery, respiratory, urology, and orthopedics treated 19.4%, 18.5%, 17.6%, 17.3%, and 13.0% of patients, respectively. Prescription patterns varied inter-department. Overall, 44.9% of patients developed SRE (bone pain requiring radiation [39.6%] or orthopedic surgery [2.9%]; hypercalcemia, 4.9%; pathological fracture, 3.3%; spinal cord compression, 0.4%). Analgesics use by patients with SREs was 1.8- to 2.2-fold in the postsymptomatic vs the presymptomatic period. SRE patients had numerically lower survival probabilities than non-SRE patients. Opioid use increased considerably in the month before death. CONCLUSION In Japanese cancer patients with bone metastases, acetaminophen, NSAIDs, and weak or strong opioids were commonly used; their use increased after SREs developed. Opioid use increased closer to death.
Collapse
Affiliation(s)
- Shingo Sato
- Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
- Department of Orthopedic Surgery, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
| | - Hideyuki Tomitori
- Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8580, Japan
| | - Atsushi Okawa
- Department of Orthopedic Surgery, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
- Yokohama City Minato Red Cross Hospital, 3-12-1 Shinyamashita, Naka-ku, Yokohama-shi, Kanagawa, 231-8682, Japan
| | - Kyoko Akano
- Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8580, Japan.
| |
Collapse
|
4
|
Vital CG, Maranhão RC, Freitas FR, Van Eyll BM, Graziani SR. Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits. J Bone Oncol 2022; 34:100431. [PMID: 35517058 PMCID: PMC9065304 DOI: 10.1016/j.jbo.2022.100431] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 04/07/2022] [Accepted: 04/12/2022] [Indexed: 11/30/2022] Open
Abstract
LDE-PTX at 175 mg/m2/3wk dose was devoid of toxicity at > 3rd line treatment. Among 18 LDE-PTX treated patients, 9 had PFS > 6 months and 2 had PFS > 1 yr. LDE-PTX diminished bone pain and improved quality of life in all treated patients.
Patients with heavily pretreated, late-stage cancer and bone metastasis are usually poor candidates for further chemotherapy. Previously, we showed that association to lipid nanoparticles (LDE) drastically decreases the toxicity of anti-cancer drugs. Here, we tested the hypothesis that paclitaxel (PTX) carried in LDE could benefit end-of-life patients with painful bone metastases that had been previously treated with conventional PTX. Methods: Eighteen consecutive patients with late-stage cancer, 8 with breast, 5 with prostate and 5 with lung carcinoma, aged 59±9 years, were included in this study. All were receiving opioid medication. LDE-PTX was administered at 175 mg/m 2 every 3 weeks until disease progression. Clinical imaging examinations and serum biochemistry determinations were performed to monitor disease progression. Intensity of bone pain, use of opioid medications and occurrence of pathological bone fractures were also evaluated. Results: In total, 104 chemotherapy cycles were performed and none of the patients showed clinical and laboratorial toxicities or pathological bone fractures. In all patients, pain was reduced so as to allow substitution of non-opioid for opioid medication. Median progression-free survival (PFS) was four months (95% CI 2.4-5.5), but in five patients PFS was longer than 6 months. Conclusions: Absence of observable clinical and laboratorial toxicities from LDE-PTX treatment, improvement of bone pain and the possible effect on PFS in some patients, despite previous use of conventional PTX, suggest that LDEPTX merits further clinical investigation.
Collapse
|
5
|
Martin-Perez AJ, Fernández-González M, Postigo-Martin P, Sampedro Pilegaard M, Fernández-Lao C, Castro-Martín E, Martín-Martín L, Lozano-Lozano M. Effectiveness of Antalgic Therapies in Patients with Vertebral Bone Metastasis: A Protocol for a Systematic Review and Meta-Analysis. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18083991. [PMID: 33920146 PMCID: PMC8069127 DOI: 10.3390/ijerph18083991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 04/05/2021] [Accepted: 04/08/2021] [Indexed: 12/02/2022]
Abstract
There is no systematic review that has identified existing studies evaluating the pharmacological and non-pharmacological intervention for pain management in patients with bone metastasis. To fill this gap in the literature, this systematic review with meta-analysis aims to evaluate the effectiveness of different antalgic therapies (pharmacological and non-pharmacological) in the improvement of pain of these patients. To this end, this protocol has been written according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) and registered in PROSPERO (CRD42020135762). A systematic search will be carried out in four international databases: Medline (Via PubMed), Web of Science, Cochrane Library and SCOPUS, to select the randomized controlled clinical trials. The Risk of Bias Tool developed by Cochrane will be used to assess the risk of bias and the quality of the identified studies. A narrative synthesis will be used to describe and compare the studies, and after the data extraction, random effects model and a subgroup analyses will be performed according to the type of intervention, if possible. This protocol aims to generate a systematic review that compiles and synthesizes the best and most recent evidence on the treatment of pain derived from vertebral metastasis.
Collapse
Affiliation(s)
- Antonio Jose Martin-Perez
- Department of Internal Medicine, San Cecilio University Hospital, Hospital Universitario San Cecilio, 18016 Granada, Spain;
- Clinical Medicine and Public Health Doctoral Studies, University of Granada, 18010 Granada, Spain
| | - María Fernández-González
- Department of Physical Therapy, Faculty of Health Sciences, University of Granada, 18010 Granada, Spain;
| | - Paula Postigo-Martin
- Biohealth Research Institute in Granada (ibs.GRANADA), 18016 Granada, Spain; (P.P.-M.); (C.F.-L.); (E.C.-M.); (M.L.-L.)
- Sport and Health University Research Institute (iMUDS), “Cuídate” Support Unit for Oncology Patients (UAPO-Cuíate), 18010 Granada, Spain
| | - Marc Sampedro Pilegaard
- Occupational Science and Occupational Therapy, The Research Unit for User Perspectives and Community-Based Interventions, Department of Public Health, University of Southern Denmark, 5230 Odense, Denmark;
- REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, 5000 Odense, Denmark
| | - Carolina Fernández-Lao
- Biohealth Research Institute in Granada (ibs.GRANADA), 18016 Granada, Spain; (P.P.-M.); (C.F.-L.); (E.C.-M.); (M.L.-L.)
- Sport and Health University Research Institute (iMUDS), “Cuídate” Support Unit for Oncology Patients (UAPO-Cuíate), 18010 Granada, Spain
| | - Eduardo Castro-Martín
- Biohealth Research Institute in Granada (ibs.GRANADA), 18016 Granada, Spain; (P.P.-M.); (C.F.-L.); (E.C.-M.); (M.L.-L.)
- Sport and Health University Research Institute (iMUDS), “Cuídate” Support Unit for Oncology Patients (UAPO-Cuíate), 18010 Granada, Spain
| | - Lydia Martín-Martín
- Biohealth Research Institute in Granada (ibs.GRANADA), 18016 Granada, Spain; (P.P.-M.); (C.F.-L.); (E.C.-M.); (M.L.-L.)
- Sport and Health University Research Institute (iMUDS), “Cuídate” Support Unit for Oncology Patients (UAPO-Cuíate), 18010 Granada, Spain
- Correspondence: ; Tel.: +34-958249004
| | - Mario Lozano-Lozano
- Biohealth Research Institute in Granada (ibs.GRANADA), 18016 Granada, Spain; (P.P.-M.); (C.F.-L.); (E.C.-M.); (M.L.-L.)
- Sport and Health University Research Institute (iMUDS), “Cuídate” Support Unit for Oncology Patients (UAPO-Cuíate), 18010 Granada, Spain
| |
Collapse
|
6
|
Ahmad I, Ahmed MM, Ahsraf MF, Naeem A, Tasleem A, Ahmed M, Farooqi MS. Pain Management in Metastatic Bone Disease: A Literature Review. Cureus 2018; 10:e3286. [PMID: 30443456 PMCID: PMC6235631 DOI: 10.7759/cureus.3286] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Accepted: 09/11/2018] [Indexed: 11/29/2022] Open
Abstract
Cancer means an uncontrolled division of abnormal cells in the body. It is a leading cause of death today. Not only the disease itself but its complications are also adding to the increase in mortality rate. One of the major complications is the pain due to metastasis of cancer. Pain is a complex symptom which has physical, psychological, and emotional impacts that influence the daily activities as well as social life. Pain acts as an alarm sign, telling the body that something is wrong. Pain can manifest in a multitude fashion. Management of bone pain due to metastasis involves different modes with some specific treatments according to the type of primary cancer. Over the years various treatment modalities have been tried and tested to improve the pain management including the use of non-steroidal anti-inflammatory drugs (NSAIDs), opioids, bisphosphonates, tricyclic antidepressants, corticosteroids, growth factors and signaling molecules, ET-1 receptor antagonists, radiotherapy as well as surgical management. The topic of discussion will cover each one of these in detail.
Collapse
Affiliation(s)
- Imama Ahmad
- Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK
| | - Munis M Ahmed
- Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK
| | | | - Anika Naeem
- Graduate, Allama Iqbal Medical College, Lahore, Pakistan, Lahore, PAK
| | - Azka Tasleem
- Internal Medicine, King Edward Medical University, Lahore, PAK
| | - Moeed Ahmed
- Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK
| | - Muhammad S Farooqi
- Internal Medicine, King Edward Medical University, Mayo Hospital, Lahore, PAK
| |
Collapse
|
7
|
Pin Y, Paix A, Le Fèvre C, Antoni D, Blondet C, Noël G. A systematic review of palliative bone radiotherapy based on pain relief and retreatment rates. Crit Rev Oncol Hematol 2018; 123:132-137. [DOI: 10.1016/j.critrevonc.2018.01.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 12/20/2017] [Accepted: 01/16/2018] [Indexed: 10/18/2022] Open
|
8
|
Elramah S, López-González MJ, Bastide M, Dixmérias F, Roca-Lapirot O, Wielanek-Bachelet AC, Vital A, Leste-Lasserre T, Brochard A, Landry M, Favereaux A. Spinal miRNA-124 regulates synaptopodin and nociception in an animal model of bone cancer pain. Sci Rep 2017; 7:10949. [PMID: 28887457 PMCID: PMC5591226 DOI: 10.1038/s41598-017-10224-1] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Accepted: 08/07/2017] [Indexed: 01/15/2023] Open
Abstract
Strong breakthrough pain is one of the most disabling symptoms of cancer since it affects up to 90% of cancer patients and is often refractory to treatments. Alteration in gene expression is a known mechanism of cancer pain in which microRNAs (miRNAs), a class of non-coding regulatory RNAs, play a crucial role. Here, in a mouse model of cancer pain, we show that miR-124 is down-regulated in the spinal cord, the first relay of the pain signal to the brain. Using in vitro and in vivo approaches, we demonstrate that miR-124 is an endogenous and specific inhibitor of synaptopodin (Synpo), a key protein for synaptic transmission. In addition, we demonstrate that Synpo is a key component of the nociceptive pathways. Interestingly, miR-124 was down-regulated in the spinal cord in cancer pain conditions, leading to an up-regulation of Synpo. Furthermore, intrathecal injections of miR-124 mimics in cancerous mice normalized Synpo expression and completely alleviated cancer pain in the early phase of the cancer. Finally, miR-124 was also down-regulated in the cerebrospinal fluid of cancer patients who developed pain, suggesting that miR-124 could be an efficient analgesic drug to treat cancer pain patients.
Collapse
Affiliation(s)
- Sara Elramah
- Bordeaux University, Bordeaux, France.,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | - María José López-González
- Bordeaux University, Bordeaux, France.,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | - Matthieu Bastide
- Bordeaux University, Bordeaux, France.,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | | | - Olivier Roca-Lapirot
- Bordeaux University, Bordeaux, France.,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | | | - Anne Vital
- Univ. Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, F-33000, France
| | - Thierry Leste-Lasserre
- INSERM U862 « Physiopathologie de l'addiction », Institut François Magendie, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | - Alexandre Brochard
- INSERM U862 « Physiopathologie de l'addiction », Institut François Magendie, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | - Marc Landry
- Bordeaux University, Bordeaux, France.,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France
| | - Alexandre Favereaux
- Bordeaux University, Bordeaux, France. .,CNRS UMR 5297 « Central mechanisms of pain sensitization », Institut Interdisciplinaire de Neuroscience, 146 rue Léo Saignat, Bordeaux Cedex, 33077, France.
| |
Collapse
|
9
|
Wang J, Zhang R, Dong C, Jiao L, Xu L, Liu J, Wang Z, Lao L. Transient Receptor Potential Channel and Interleukin-17A Involvement in LTTL Gel Inhibition of Bone Cancer Pain in a Rat Model. Integr Cancer Ther 2016; 14:381-93. [PMID: 26100378 DOI: 10.1177/1534735415580677] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Cancer pain management is a challenge for which Chinese herbal medicine might be useful. To study the spinal mechanisms of the Chinese medicated gel Long-Teng-Tong-Luo (LTTL), a 7-herb compound, on bone cancer pain, a bone cancer pain model was made by inoculating the tibias of female rats with Walker 256 cells. LTTL gel or inert gel, 0.5 g/cm(2)/d, was applied to the skin of tumor-bearing tibias for 21 days beginning a day after the inoculation. Mechanical threshold and paw withdrawal latency to thermal stimulation was measured. Transient receptor potential (TRP) cation channels in lumbar dorsal root ganglia (DRG) were immunostained and counted, and lumbar spinal cord interleukin-17A (IL-17A) was measured with real-time polymerase chain reaction and enzyme-linked immunosorbent assay. TRP antagonists and interleukin (IL)-17A antibodies were intrathecally administered to determine their effects on bone cancer pain. The gel significantly (P < .05) alleviated cancer-induced mechanical allodynia and thermal hyperalgesia and inhibited cancer-enhanced expression of IL-17A in spinal astrocytes and the TRP subfamily members V1, A1, and V4 in lumbar DRG. Intrathecal TRP antagonists at 10 µg significantly (P < .05) attenuated mechanical allodynia, thermal hyperalgesia, and IL-17A expression, indicating that TRP channels facilitate spinal IL-17 expression and cancer pain. IL-17A antibodies inhibited cancer pain, suggesting that IL-17A promotes such pain. The data show that LTTL gel inhibits cancer pain, and this might be accounted for by the decrease in expression of DRG TRP channels and spinal astrocyte IL-17A.
Collapse
Affiliation(s)
- Juyong Wang
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Ruixin Zhang
- Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
| | - Changsheng Dong
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Lijing Jiao
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Ling Xu
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Jiyong Liu
- The Ministry of Education Key Laboratory for Standardization of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Zhengtao Wang
- The Ministry of Education Key Laboratory for Standardization of Chinese Medicines, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Lixing Lao
- Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA
| |
Collapse
|
10
|
Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY. Advances in cancer pain from bone metastasis. DRUG DESIGN DEVELOPMENT AND THERAPY 2015; 9:4239-45. [PMID: 26316696 PMCID: PMC4547660 DOI: 10.2147/dddt.s87568] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
With the technological advances in cancer diagnosis and treatment, the survival rates for patients with cancer are prolonged. The issue of figuring out how to improve the life quality of patients with cancer has become increasingly prominent. Pain, especially bone pain, is the most common symptom in malignancy patients, which seriously affects the life quality of patients with cancer. The research of cancer pain has a breakthrough due to the development of the animal models of cancer pain in recent years, such as the animal models of mouse femur, humerus, calcaneus, and rat tibia. The establishment of several kinds of animal models related to cancer pain provides a new platform in vivo to investigate the molecular mechanisms of cancer pain. In this review, we focus on the advances of cancer pain from bone metastasis, the mechanisms involved in cancer pain, and the drug treatment of cancer pain in the animal models.
Collapse
Affiliation(s)
- Xiao-Cui Zhu
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Jia-Li Zhang
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Chen-Tao Ge
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Yuan-Yang Yu
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Pan Wang
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China
| | - Ti-Fei Yuan
- School of Psychology, Nanjing Normal University, Nanjing, People's Republic of China
| | - Cai-Yun Fu
- College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People's Republic of China ; Institute for Cell-Based Drug Development of Zhejiang Province, Hangzhou, People's Republic of China
| |
Collapse
|
11
|
Sun H, Zang X, Liu Y, Cao X, Wu F, Huang X, Jiang M, Zhang X. Expression of a chimeric human/salmon calcitonin gene integrated into the Saccharomyces cerevisiae genome using rDNA sequences as recombination sites. Appl Microbiol Biotechnol 2015; 99:10097-106. [PMID: 26254786 DOI: 10.1007/s00253-015-6834-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 07/08/2015] [Accepted: 07/11/2015] [Indexed: 11/26/2022]
Abstract
Calcitonin participates in controlling homeostasis of calcium and phosphorus and plays an important role in bone metabolism. The aim of this study was to endow an industrial strain of Saccharomyces cerevisiae with the ability to express chimeric human/salmon calcitonin (hsCT) without the use of antibiotics. To do so, a homologous recombination plasmid pUC18-rDNA2-ura3-P pgk -5hsCT-rDNA1 was constructed, which contains two segments of ribosomal DNA of 1.1 kb (rDNA1) and 1.4 kb (rDNA2), to integrate the heterologous gene into host rDNA. A DNA fragment containing five copies of a chimeric human/salmon calcitonin gene (5hsCT) under the control of the promoter for phosphoglycerate kinase (P pgk ) was constructed to express 5hsCT in S. cerevisiae using ura3 as a selectable auxotrophic marker gene. After digestion by restriction endonuclease HpaI, a linear fragment, rDNA2-ura3-P pgk -5hsCT-rDNA1, was obtained and transformed into the △ura3 mutant of S. cerevisiae by the lithium acetate method. The ura3-P pgk -5hsCT sequence was introduced into the genome at rDNA sites by homologous recombination, and the recombinant strain YS-5hsCT was obtained. Southern blot analysis revealed that the 5hsCT had been integrated successfully into the genome of S. cerevisiae. The results of Western blot and ELISA confirmed that the 5hsCT protein had been expressed in the recombinant strain YS-5hsCT. The expression level reached 2.04 % of total proteins. S. cerevisiae YS-5hsCT decreased serum calcium in mice by oral administration and even 0.01 g lyophilized S. cerevisiae YS-5hsCT/kg decreased serum calcium by 0.498 mM. This work has produced a commercial yeast strain potentially useful for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Hengyi Sun
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Xiaonan Zang
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China.
| | - Yuantao Liu
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Xiaofei Cao
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Fei Wu
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Xiaoyun Huang
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Minjie Jiang
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| | - Xuecheng Zhang
- Key Laboratory of Marine Genetics and Breeding, Ministry of Education, Ocean University of China, 5 Yushan Road, Qingdao, 266003, People's Republic of China
| |
Collapse
|
12
|
Kapoor A, Singhal MK, Bagri PK, Nirban RK, Maharia S, Narayan S, Kumar HS. Comparison of single versus multiple fractions for palliative treatment of painful bone metastasis: first study from north west India. Indian J Palliat Care 2015; 21:45-8. [PMID: 25709185 PMCID: PMC4332127 DOI: 10.4103/0973-1075.150178] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: Bone metastasis is a usual cause of pain in advanced cancer. Conventional radiation schedules require larger hospital stay and thus are not suitable for patients with poor general condition. This prospective observational study aims to compare the pain-relieving efficacy of different radiation fractionation schedules, i.e., 8 Gy administered in a single fraction versus 30 Gy administered in 10 fractions. Materials and Methods: Two hundred and fifty consecutive patients of bone metastasis were evaluated for the study, with 63 patients being excluded due to non-fulfillment of the inclusion criteria. The response to radiotherapy leading to pain relief as per the Visual Analog Scale was recorded at the end of treatment, 8 days, 15 days and 1 month during the follow-up visits. Results: Sixty-two percent of the patients received a single fraction while the remaining received 10 fractions. In the 10-fraction group, overall response was present in 60% of the patients. Stable pain was present in 23% of the patients while 9% patients had progressive pain. At 1 month of completion of treatment, 9% patients were lost to follow-up. In the single-fraction arm, overall response was seen in 58%, stable pain in 27% and progressive pain in 7% of the patients. Six percent of the patients were lost to follow-up. Conclusions: Single-fraction treatment for bony metastasis is as effective as multiple fractions to relieve bony pain and provides treatment convenience to both the patient and the caregiver.
Collapse
Affiliation(s)
- Akhil Kapoor
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Mukesh Kumar Singhal
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Puneet Kumar Bagri
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Raj Kumar Nirban
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Sitaram Maharia
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Satya Narayan
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| | - Harvindra Singh Kumar
- Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
| |
Collapse
|
13
|
Abstract
Pain is a major symptom of bone cancer. Bone cancer pain significantly affects quality of life, but its underlying mechanisms have not been defined. Because skeletal metastases are particularly common in patients with prostate cancer, a model that mimics bone cancer pain has been established by injecting AT-3.1 prostate cancer cells into the tibia of the male Copenhagen rat. The model shows progressive hyperalgesia and allodynia that are associated with the gradual destruction of the tibia and can be used to study the mechanisms, such as glial activation, of these disorders.
Collapse
Affiliation(s)
- Ruixin Zhang
- Center For Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA.
| | | |
Collapse
|
14
|
Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 2008; 154:1533-8. [PMID: 18554806 DOI: 10.1016/j.neuroscience.2008.04.072] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2007] [Revised: 04/14/2008] [Accepted: 04/16/2008] [Indexed: 01/17/2023]
Abstract
It has been shown that interleukin-1beta (IL-1beta) facilitates nociception during neuropathic and inflammatory pain, but its involvement in bone cancer pain and its mechanisms have not previously been established. This study is an investigation of IL-1beta spinal expression and the N-methyl-D-aspartate (NMDA) receptor (NMDAR) NR1 subunit phosphorylation during cancer pain, co-localization of IL-1 receptor type I (IL-1RI) and NMDAR in the spinal cord, and the effects of IL-1 receptor antagonist (IL-1ra) on NMDAR1 (NR1) phosphorylation and hyperalgesia in a rat model of bone cancer pain. Cancer was induced by injecting AT-3.1 prostate cancer cells into the tibia of the male Copenhagen rat. Phosphorylation of NR1, an essential subunit of the NMDAR, is known to modulate NMDAR activity and facilitate pain. Mechanical hyperalgesia, established by a decrease in paw withdrawal pressure threshold (PWPT), was measured at baseline and 2 h after IL-1ra treatment. IL-1ra was given (i.t.) daily for 7 days between days 13 and 19 after the cancer cell inoculation. Spinal cords were removed for Western blot to measure IL-1beta and NR1 phosphorylation and for double immunostaining of IL-1RI and NR1. The data showed that 1) spinal IL-1beta was up-regulated and NR1 phosphorylation was increased, 2) IL-1ra at 0.1 mg/rat significantly (P<0.05) inhibited mechanical hyperalgesia, increasing PWPT on day 14 from 71.1+/-3.1-85.3+/-4.6 g and on day 19 from 73.5.0+/-3.5-87.1+/-3.7 g, and inhibited NR1 phosphorylation compared with saline control, and 3) IL-1RI is localized in NR1-immunoreactive neurons within the spinal cord. The results suggest that spinal IL-1beta enhances NR1 phosphorylation to facilitate bone cancer pain.
Collapse
|
15
|
Zhang RX, Li A, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L. Electroacupuncture Attenuates Bone Cancer Pain and Inhibits Spinal Interleukin-1β Expression in a Rat Model. Anesth Analg 2007; 105:1482-8, table of contents. [DOI: 10.1213/01.ane.0000284705.34629.c5] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
16
|
Cancer avancé de la prostate et maladie osseuse métastatique. ONCOLOGIE 2007. [DOI: 10.1007/s10269-007-0722-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Zhang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM, Lao L. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005; 118:125-36. [PMID: 16154703 DOI: 10.1016/j.pain.2005.08.001] [Citation(s) in RCA: 158] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2005] [Revised: 07/19/2005] [Accepted: 08/01/2005] [Indexed: 01/23/2023]
Abstract
Studies suggest that astrocytes and microglia in the spinal cord are involved in the development of persistent pain induced by tissue inflammation and nerve injury. However, the role of glial cells in bone cancer pain is not well understood. The present study evaluated the spinal glial activation in a novel rat model of bone cancer pain produced by injecting AT-3.1 prostate cancer cells into the unilateral tibia of male Copenhagen rats. The structural damage to the tibia was monitored by radiological analysis. The thermal hyperalgesia, mechanical hyperalgesia and allodynia, and spontaneous flinch were measured. The results showed that: (1) inoculation of prostate cancer cells, but not the vehicle Hank's solution, induced progressive bone destruction at the proximal epiphysis of the tibia from day 7-20 post inoculation; (2) the inoculation also induced progressive thermal hyperalgesia, mechanical hyperalgesia, mechanical allodynia, and spontaneous flinches; (3) astrocytes and microglia were significantly activated in the spinal cord ipsilateral to the cancer leg, characterized by enhanced immunostaining of both glial fibrillary acidic protein (GFAP, astrocyte marker) and OX-42 (microglial marker); (4) IL-1beta was up-regulated in the ipsilateral spinal cord, evidenced by an increase of IL-1beta immunostained astrocytes. These results demonstrate that injection of AT-3.1 prostate cancer cells into the tibia produces progressive hyperalgesia and allodynia associated with the progression of tibia destruction, indicating the successful establishment of a novel male rat model of bone cancer pain. Further, bone cancer activates spinal glial cells, which may release IL-1beta and other cytokines and contribute to hyperalgesia.
Collapse
Affiliation(s)
- Rui-Xin Zhang
- Center For Integrative Medicine, School of Medicine, University of Maryland, 3rd Floor, James Kernan Hospital Mansion, 2200 Kernan Drive, Baltimore, MD 21207, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Gilchrist LS, Cain DM, Harding-Rose C, Kov AN, Wendelschafer-Crabb G, Kennedy WR, Simone DA. Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. Brain Res 2005; 1044:197-205. [PMID: 15885218 DOI: 10.1016/j.brainres.2005.02.081] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2004] [Revised: 02/18/2005] [Accepted: 02/23/2005] [Indexed: 10/25/2022]
Abstract
To determine whether ATP and P2X3 receptors contribute to bone-cancer pain in a mouse model, immunohistochemical techniques were used to identify whether changes in the labeling of P2X3 receptors on epidermal nerve fibers (ENFs) occurred during tumor development. C3H mice were injected with osteolytic fibrosarcoma cells in and around the calcaneus bone. These mice exhibited mechanical hyperalgesia by day 10 post-implantation as assessed using von Frey monofilaments. Biopsies of the plantar skin overlying the tumor were obtained at days 10, 14, and 18 post-implantation. Confocal images were analyzed for the number of PGP 9.5, P2X3, and CGRP immunoreactive (ir) ENFs. The overall ENF population (PGP-ir) decreased progressively over time, whereas the subsets of P2X3-ir fibers demonstrated a modest increase and CGRP-ir nerve fibers remained fairly constant. Importantly, the proportion of CGRP-ir fibers that labeled for P2X3 increased from approximately 6% in control animals to nearly 30% at day 14 following tumor cell implantation. These studies demonstrate increased expression of P2X3 receptors on CGRP-ir ENFs during tumor growth and suggest a role for ATP in cancer-related pain.
Collapse
Affiliation(s)
- Laura S Gilchrist
- Physical Therapy Program, College of St. Catherine, Minneapolis, MN 55454, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Cohen MZ, Easley MK, Ellis C, Hughes B, Ownby K, Rashad BG, Rude M, Taft E, Westbrooks JB. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage 2003; 25:519-27. [PMID: 12782432 DOI: 10.1016/s0885-3924(03)00068-x] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Unrelieved pain is a major medical problem. In response to this problem, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) launched new standards for pain management in 1999. A review was conducted in five hospitals of 117 charts of 80 inpatients and 37 outpatients with cancer who had pain documented in their medical records to determine whether application of these JCAHO standards was documented. Pain assessment and management were not documented for most patients. Pain intensity was noted for 57% of outpatients and 53% of inpatients. When pain was documented, treatment was noted in 86% of outpatients' charts and 89% of inpatients' charts. Of those patients with documented pain, reassessment after treatment was reported in 34% of the outpatient charts and 44% of the inpatient charts. Work to properly manage cancer pain needs to continue, and the JCAHO standards provide a mechanism to evaluate practice documentation in order to improve care.
Collapse
Affiliation(s)
- Marlene Zichi Cohen
- School of Nursing, The University of Texas-Houston Health Science Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 2002. [PMID: 11717369 DOI: 10.1523/jneurosci.21-23-09355.2001] [Citation(s) in RCA: 148] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
This paper describes a model of tumor-induced bone destruction and hyperalgesia produced by implantation of fibrosarcoma cells into the mouse calcaneus bone. Histological examination indicates that tumor cells adhere to the bone edge as early as post-implantation day (PID) 3, but osteolysis does not begin until PID 6, correlating with the development of hyperalgesia. C3H/He mice exhibit a reproducible hyperalgesia to mechanical and cold stimuli between PID 6 and 16. These behaviors are present but significantly reduced with subcutaneous implantation that does not involve bone. Systemic administration of morphine (ED(50) 9.0 mg/kg) dose-dependently attenuated the mechanical hyperalgesia. In contrast, bone destruction and hypersensitivity were not evident in mice implanted with melanoma tumors or a paraffin mass of similar size. A novel microperfusion technique was used to identify elevated levels of the putative algogen endothelin (ET) in perfusates collected from the tumor sites of hyperalgesic mice between PID 7 and 12. Increased ET was evident in microperfusates from fibrosarcoma tumor-implanted mice but not from melanoma tumor-implanted mice, which are not hyperalgesic. Intraplantar injection of ET-1 in naive and, to a greater extent, fibrosarcoma tumor-bearing mice produced spontaneous pain behaviors, suggesting that ET-1 activates primary afferent fibers. Intraplantar but not systemic injection of the ET-A receptor antagonist BQ-123 partially blocked tumor-associated mechanical hyperalgesia, indicating that ET-1 contributes to tumor-induced nociception. This model provides a unique approach for quantifying the behavioral, biochemical, and electrophysiological consequences of tumor-nerve interactions.
Collapse
|